Back to top

Philip Morris Curtails View on Montreal Legal Proceedings

Read MoreHide Full Article

Philip Morris International Inc. (PM - Free Report) trimmed its earnings view for 2019. The move came after the Court of Appeal in Montreal gave its punitive judgment against Rothmans, Benson & Hedges Inc., a subsidiary of Philip Morris. Let’s take a closer look at the latest development.

Lawsuit Leads to View Cut

The lawsuit is related to a trail in 2015, wherein the defendants — Rothmans, Benson & Hedges, Imperial Tobacco Canada Limited and JTI-Macdonald Corp — were accused for serious damages. On Mar 1, 2019, the court ruled against the defendants and as a result the parties involved are to bear a lumpsum amount as compensation.

As a result of this move, Rothmans, Benson & Hedges is required to deposit CAD 257 million, of which CAD 226 million had been earlier deposited as security. Thanks to such litigations, Philip Morris is likely to bear pre-tax charge of nearly $194 million in the first quarter of 2019.  Management will be assessing the developments associated with this case and has hence stated that the estimated charges are subject to changes in the future.

Consequently, the company curtailed its earnings view for 2019 to reflect the aforementioned legal expenses. The company currently expects reported earnings to be nearly $5.28 compared with the earlier forecast of $5.37. The revised earnings projection is based on the exchange rates as of Feb 7, 2019, when the company released fourth-quarter 2018 results. Excluding the impacts of unfavorable currency of approximately 14 cents and legal charges of 9 cents, earnings are projected to rise 8% year on year.



Wrapping Up

Apart from the adverse impacts of legal proceedings and currency, declining shipment volumes, especially for cigarettes, are a concern. In fact, management anticipates cigarette and heated tobacco shipment volumes to decline in the range of 1.5-2% in 2019.

Nevertheless, this Zacks Rank #2 (Buy) company expects to cushion these hurdles on the back of strong pricing strategies. Evidently, higher pricing in the combustible tobacco portfolio has been supporting performance for a while. Moreover, price hikes enable Philip Morris to maintain margins at the desired level. The company continues to expect pricing to remain a key growth driver in the near term.

Apart from this, growth in the heated tobacco products arena is an upside to the company’s performance. Rising health awareness have pushed consumers toward low-risk tobacco products. In fact, the company’s IQOS devices are among one of the leading reduced risk products (RRPs) in the industry. Going forward, the company expects consistent growth in IQOS and Heated Tobacco category and is on track with investments in the category.

To top these, this well-known tobacco player is likely to continue gaining from a strong brand portfolio, comprising renowned names such as Marlboro, L&M, Bond Street, Parliament, Chesterfield and Virginia Slims among others. Such aspects are boosting investors’ optimism on the stock that has gained 14.4% in the past six months, while the industry declined 3.5%.

Greedy for Consumer Staples Stocks? Check These

The Estee Lauder Companies (EL - Free Report) has long-term earnings per share (EPS) growth rate of 12.4% and currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here..

General Mills (GIS - Free Report) has a long-term EPS growth rate of 7.3% and currently carries a Zacks Rank #2.

Lamb Weston Holdings (LW - Free Report) has a long-term EPS growth rate of 12% and holds a Zacks Rank #2 at present.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



More from Zacks Analyst Blog

You May Like